PTB
MCID: PLM001
MIFTS: 67

Pulmonary Tuberculosis (PTB) malady

Categories: Infectious diseases

Aliases & Classifications for Pulmonary Tuberculosis

Aliases & Descriptions for Pulmonary Tuberculosis:

Name: Pulmonary Tuberculosis 12 14
Tuberculosis, Pulmonary 42 69
Tuberculosis Pulmonary 52
Ptb 45

Classifications:



External Ids:

Disease Ontology 12 DOID:2957
ICD10 33 A15 A15.0
ICD9CM 35 011 011.9 011.90
MeSH 42 D014397
NCIt 47 C26899
UMLS 69 C0041327

Summaries for Pulmonary Tuberculosis

Disease Ontology : 12 A tuberculosis that is a contagious disease located in lungs. The infection has symptom fever, has symptom cough, has symptom difficulty in breathing, has symptom inflammatory infiltrations, has symptom formation of tubercles, has symptom caseation, has symptom pleural effusion, and has symptom fibrosis.

MalaCards based summary : Pulmonary Tuberculosis, also known as tuberculosis, pulmonary, is related to tuberculosis and hepatitis, and has symptoms including fever, cough and difficulty in breathing. An important gene associated with Pulmonary Tuberculosis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Priftin and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Pulmonary Tuberculosis

Diseases related to Pulmonary Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
id Related Disease Score Top Affiliating Genes
1 tuberculosis 31.8 IL10 IL2 IL4 TNF
2 hepatitis 30.3 HLA-DRB1 IFNG IL10 IL2 TNF
3 cryptococcosis 29.8 HLA-DRB1 IL10 TNF
4 asbestosis 29.8 IL10 TLR2 TNF
5 anaplastic large cell lymphoma 29.5 IFNG IL2 TNF VDR
6 nasopharyngitis 29.5 IFNG IL2 IL4 TNF
7 elephantiasis 29.5 ADA IFNG IL10
8 epidermolysis bullosa 29.4 IFNG IL18 IL4 TNF
9 pulmonary eosinophilia 29.2 ADA IFNG IL10 MBL2 TLR2 TNF
10 rheumatoid arthritis 29.1 CCL3 HLA-DRB1 IFNG IL10 IL18 IL2
11 laryngeal tuberculosis 11.1
12 miliary tuberculosis 10.8
13 nosophobia 10.8
14 pyridoxal 5'-phosphate-dependent epilepsy 10.4 IL10 TNF
15 myoglobinuria recurrent 10.4 IFNG IL4
16 distal trisomy 14q 10.3 HLA-DRB1 IFNG TNF
17 steatitis 10.3 IL2 TNF
18 parkinson disease 11 10.3 IFNG IL10 TNF
19 myofibroma 10.3 HLA-DRB1 IFNG IL10
20 senile reticular retinal degeneration 10.3 IFNG IL10 TNF
21 conduct disorder 10.3 IFNG IL10 TNF
22 intravascular papillary endothelial hyperplasia 10.3 IFNG IFNGR1
23 pulpitis 10.3 IFNG IL10 TNF
24 phlyctenulosis 10.3 IL10 MBL2 TNF
25 caplan's syndrome 10.3 HLA-DRB1 IFNG IL2
26 amyotrophic lateral sclerosis type 14 10.3 IFNG IL2 TNF
27 parametritis 10.3 IFNG IL2 TNF
28 ethmoid sinus cancer 10.3 IFNG SLC11A1 VDR
29 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 IL4 TNF
30 urethral intrinsic sphincter deficiency 10.3 IFNG IL4 TNF
31 benign deep fibrous histiocytoma 10.3 HLA-DRB1 IFNG TNF
32 asymptomatic neurosyphilis 10.3 IFNG IL10 IL4
33 erb-duchenne and dejerine-klumpke palsies 10.3 IFNG IL10 TNF
34 hypotrichosis 4 10.3 IFNG IL4 TNF
35 lagophthalmos 10.3 IL10 IL4 TNF
36 tungiasis 10.3 IFNG IL10 IL4
37 aseptic meningitis 10.3 HLA-DRB1 TLR2 TNF
38 conidiobolomycosis 10.3 IL10 IL4 TNF
39 venezuelan hemorrhagic fever 10.3 IFNG IL2 TNF
40 vestibule of mouth cancer 10.3 IL10 IL4 TNF
41 reproductive system disease 10.3 HLA-DRB1 IL10 TLR2
42 chronic thromboembolic pulmonary hypertension 10.3 IFNG IL10 IL2
43 primary ciliary dyskinesia 10.3 IL10 SLC11A1 TNF
44 follicular adenoma 10.3 IFNG IL10 TNF
45 low anorectal malformation 10.3 HLA-DRB1 IL10 TNF
46 ectothrix infectious disease 10.3 IFNG MBL2 TLR2
47 oral cavity cancer 10.3 IFNG IL4 TNF
48 leukoplakia of vagina 10.3 TLR2 TNF VDR
49 multiple epiphyseal dysplasia due to collagen 9 anomaly 10.3 IFNG IL2 IL4
50 immunoglobulin g deficiency 10.3 HLA-DRB1 IL10 TNF

Comorbidity relations with Pulmonary Tuberculosis via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchiectasis
Bronchitis Deficiency Anemia
Heart Disease Iron Deficiency Anemia
Pleural Tuberculosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Pulmonary Tuberculosis:



Diseases related to Pulmonary Tuberculosis

Symptoms & Phenotypes for Pulmonary Tuberculosis

Symptoms:

12
  • fever
  • cough
  • difficulty in breathing
  • inflammatory infiltrations
  • formation of tubercles
  • caseation
  • pleural effusion
  • fibrosis

UMLS symptoms related to Pulmonary Tuberculosis:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Tuberculosis:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 SLC11A1 TLR2 TNF VDR ADA HP
2 homeostasis/metabolism MP:0005376 10.36 ADA HP IFNG IFNGR1 IL10 IL12RB1
3 immune system MP:0005387 10.34 ADA HP IFNG IFNGR1 IL10 IL12RB1
4 cardiovascular system MP:0005385 10.31 ADA HP IFNG IFNGR1 IL10 IL18
5 digestive/alimentary MP:0005381 10.29 SLC11A1 TLR2 TNF VDR ADA IFNG
6 cellular MP:0005384 10.26 IFNGR1 IL10 IL18 IL2 IL4 P2RX7
7 endocrine/exocrine gland MP:0005379 10.19 ADA IFNG IFNGR1 IL10 IL2 IL4
8 mortality/aging MP:0010768 10.13 ADA HP IFNG IFNGR1 IL10 IL18
9 liver/biliary system MP:0005370 10.07 TLR2 TNF ADA HP IFNG IFNGR1
10 integument MP:0010771 10.06 IFNG IFNGR1 IL10 IL18 IL4 P2RX7
11 neoplasm MP:0002006 9.91 HP IFNG IFNGR1 IL10 IL2 INHA
12 renal/urinary system MP:0005367 9.76 IL4 MBL2 TLR2 VDR ADA HP
13 reproductive system MP:0005389 9.65 INHA NAT2 TNF VDR ADA IFNG
14 skeleton MP:0005390 9.32 ADA IFNG IFNGR1 IL10 IL4 INHA

Drugs & Therapeutics for Pulmonary Tuberculosis

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Priftin 17 RIFAPENTINE Hoechst Marion Roussel Approved June 1998

Drugs for Pulmonary Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 368)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
2
Ethambutol Approved Phase 4,Phase 3,Phase 2,Phase 1 74-55-5 3279 14052
3
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
4
Isoniazid Approved Phase 4,Phase 3,Phase 2,Phase 1 54-85-3 3767
5
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 354812-41-2, 151096-09-2 152946
6
Norgestimate Approved Phase 4,Phase 3,Phase 2,Phase 1 35189-28-7 6540478
7
Pyrazinamide Approved Phase 4,Phase 3,Phase 2,Phase 1 98-96-4 1046
8
Rifabutin Approved Phase 4,Phase 3,Phase 2 72559-06-9 6323490
9
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
10
Streptomycin Approved, Vet_approved Phase 4,Phase 2,Phase 1 57-92-1 19649
11
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
12
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
13
Efavirenz Approved, Investigational Phase 4,Phase 2 154598-52-4 64139
14
Emtricitabine Approved, Investigational Phase 4,Phase 2 143491-57-0 60877
15
Tenofovir Approved, Investigational Phase 4,Phase 2 147127-20-6 464205
16
Calcium carbonate Approved Phase 4,Phase 3 471-34-1
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
19
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
20
Zidovudine Approved Phase 4 30516-87-1 35370
21
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
22
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
23
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
24
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 10883523 5280795
25 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
29 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1
32 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2,Phase 1
33 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
34 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1
35 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1
36 Estradiol valerate Phase 4,Phase 3,Phase 2,Phase 1 979-32-8
37 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Norgestimate, ethinyl estradiol drug combination Phase 4,Phase 3,Phase 2,Phase 1
40 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
41 Polyestradiol phosphate Phase 4,Phase 3,Phase 2,Phase 1
42 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
43 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
44 Ergocalciferols Phase 4,Phase 3,Phase 2
45 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
46 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
47 vitamin d Phase 4,Phase 3,Phase 2
48 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
49 Antiviral Agents Phase 4,Phase 3,Phase 2
50 Interferon-gamma Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 408)
id Name Status NCT ID Phase
1 Research on New Regimens for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4
2 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4
3 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis Unknown status NCT02464683 Phase 4
4 Simple Verbal Intervention for Adequately Collecting Sputum Unknown status NCT01135043 Phase 4
5 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4
6 Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children Unknown status NCT00604617 Phase 4
7 Epidemiology of MDR-TB in Peru Unknown status NCT00676754 Phase 4
8 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
9 MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis Completed NCT00495339 Phase 4
10 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
11 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4
12 Improving Community Based Tuberculosis Care in Ethiopia Completed NCT00803322 Phase 4
13 The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis Completed NCT00939419 Phase 4
14 Ultrathin Bronchoscopy for Solitary Pulmonary Nodules Completed NCT02490059 Phase 4
15 Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea Completed NCT00864812 Phase 4
16 QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study. Completed NCT01223534 Phase 4
17 Investigation of the Effect of Systemic Steroids on Treatment and Prevention of Recurrent Tracheal Stenosis in Postoperative Patients Completed NCT02855502 Phase 4
18 The Effects of Atorvastatin Treatment in COPD Patients Completed NCT01748279 Phase 4
19 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
20 Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis Recruiting NCT02901288 Phase 4
21 Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation Recruiting NCT02231229 Phase 4
22 Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 Recruiting NCT02057796 Phase 4
23 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis Not yet recruiting NCT02169570 Phase 4
24 Prevention of Tuberculosis in Prisons Not yet recruiting NCT03028129 Phase 4
25 The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acetylcysteine (NAC) Not yet recruiting NCT02889757 Phase 4
26 The Applicability of Different Scoring Systems and Use of Steroids in the Treatment of Hospital Acquired Pneumonia Not yet recruiting NCT03121690 Phase 4
27 Assessment and Tracking of Long-term Alefacept Safety Terminated NCT00454701 Phase 4
28 Latency in Pulmonary Tuberculosis Unknown status NCT01154959 Phase 3
29 Efficacy of Oral Zinc Administration as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients Unknown status NCT00698386 Phase 3
30 Pulmonary Tuberculosis and Vitamin D Unknown status NCT00507000 Phase 3
31 A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216385 Phase 3
32 Development of Tuberculosis Diagnostic Kit Unknown status NCT00311207 Phase 3
33 Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) Unknown status NCT01398618 Phase 3
34 Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis Unknown status NCT00376012 Phase 3
35 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3
36 Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide Unknown status NCT02120638 Phase 3
37 Study of Picoplatin Efficacy After Relapse Unknown status NCT00465491 Phase 3
38 L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB) Completed NCT00677339 Phase 3
39 Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. Completed NCT00341328 Phase 3
40 Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis Completed NCT00864383 Phase 3
41 Nutrition, Diabetes and Pulmonary TB/HIV Completed NCT00311298 Phase 3
42 Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients Completed NCT00265226 Phase 3
43 Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis Completed NCT00801606 Phase 3
44 Trial of Adjunctive Vitamin D in Tuberculosis Treatment Completed NCT00419068 Phase 3
45 A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients Completed NCT00366470 Phase 3
46 TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis Completed NCT00023335 Phase 3
47 Vitamin A Therapy for Tuberculosis Completed NCT00057434 Phase 3
48 Tuberculosis Treatment Shortening Trial Completed NCT00130247 Phase 3
49 The Treatment of Tuberculosis in HIV-Infected Patients Completed NCT00001033 Phase 3
50 Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV Completed NCT01061593 Phase 3

Search NIH Clinical Center for Pulmonary Tuberculosis

Cochrane evidence based reviews: tuberculosis, pulmonary

Genetic Tests for Pulmonary Tuberculosis

Anatomical Context for Pulmonary Tuberculosis

MalaCards organs/tissues related to Pulmonary Tuberculosis:

39
Lung, T Cells, Testes, Monocytes, Neutrophil, Skin, Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Pulmonary Tuberculosis:

18
Lungs

Publications for Pulmonary Tuberculosis

Articles related to Pulmonary Tuberculosis:

(show top 50) (show all 1261)
id Title Authors Year
1
Unbiased Identification of Blood-based Biomarkers for Pulmonary Tuberculosis by Modeling and Mining Molecular Interaction Networks. ( 28065665 )
2017
2
Pulmonary tuberculosis presenting as post-operative fever of unknown origin. ( 28062417 )
2017
3
Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management. ( 28076011 )
2017
4
A novel role of Yin-Yang-1 in pulmonary tuberculosis through the regulation of the chemokine CCL4. ( 26786659 )
2016
5
Association of DC-SIGN and DC-SIGNR Repeat Regions with Susceptibility to Pulmonary Tuberculosis in Zahedan, Southeastern Iran. ( 27309478 )
2016
6
MiRNA-155 and miRNA-132 as potential diagnostic biomarkers for pulmonary tuberculosis: A preliminary study. ( 27616444 )
2016
7
Diagnostic delay of pulmonary tuberculosis in patients with acute respiratory distress syndrome associated with aspiration pneumonia: Two case reports and a mini-review from Japan. ( 27446284 )
2016
8
The Impact of Treatment on the Serum Concentration of Interleukin-1 Beta in Pulmonary Tuberculosis. ( 27661435 )
2016
9
Extra pulmonary tuberculosis presenting as fever with massive splenomegaly and pancytopenia. ( 27051579 )
2016
10
Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. ( 27186634 )
2016
11
Xpert(Ar) MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children. ( 27155190 )
2016
12
Efficacy and safety of quercetin and polyvinylpyrrolidone in treatment of patients with newly diagnosed destructive pulmonary tuberculosis in comparison with standard antimycobacterial therapy. ( 28043493 )
2016
13
New-Data Letter - A< Assessment of microbiological diagnosis of active pulmonary tuberculosis: culture on liquid media with or without solid media A>. ( 27654335 )
2016
14
Immunological Roles of Elevated Plasma Levels of Matricellular Proteins in Japanese Patients with Pulmonary Tuberculosis. ( 28025511 )
2016
15
Cerebral aspergillosis and pulmonary tuberculosis in a child with chronic granulomatous disease. ( 27308089 )
2016
16
Comparative proteomic analysis of sequential isolates of Mycobacterium tuberculosis sensitive and resistant Beijing type from a patient with pulmonary tuberculosis. ( 28043501 )
2016
17
Massive hemoptysis due to intercostal artery aneurysm in pulmonary tuberculosis. ( 27209842 )
2016
18
The NRAMP1, VDR, TNF-I+, ICAM1, TLR2 and TLR4 gene polymorphisms in Iranian patients with pulmonary tuberculosis: A case-control study. ( 26774366 )
2016
19
Streptomycin for Pulmonary Tuberculosis. ( 27153509 )
2016
20
Factors associated with mortality among patients with active pulmonary tuberculosis requiring intensive care. ( 27653545 )
2016
21
Frequency of hypovitaminosis D and its associated risk factors in newly diagnosed pulmonary tuberculosis patients. ( 27182266 )
2016
22
Identification of promising plasma immune biomarkers to differentiate active pulmonary tuberculosis. ( 27591510 )
2016
23
Chromoblastomycosis due to Fonsecaea monophora misdiagnosed as sporotrichosis and cutaneous tuberculosis in a pulmonary tuberculosis patient. ( 27330937 )
2016
24
The contribution of the sympathetic nervous system to the immunopathology of experimental pulmonary tuberculosis. ( 27609282 )
2016
25
Genotypic analysis of multidrug-resistant tuberculosis isolates from extra pulmonary tuberculosis cases in tertiary care centers in Northern India. ( 28043502 )
2016
26
Using competing risks model and competing events in outcome of pulmonary tuberculosis patients. ( 28043578 )
2016
27
Alleles of HLA-DRB1*04 Associated with Pulmonary Tuberculosis in Amazon Brazilian Population. ( 26901036 )
2016
28
High Beclin-1 Expression in Human Alveolar Macrophage Significantly Correlate with the Bacteriologic Sterilization in Pulmonary Tuberculosis Patients. ( 27468561 )
2016
29
Influence of the polymorphism of the DUSP14 gene on the expression of immune-related genes and development of pulmonary tuberculosis. ( 26938665 )
2016
30
Dental technician pneumoconiosis mimicking pulmonary tuberculosis: a case report. ( 27604085 )
2016
31
Comparison of single nucleotide polymorphisms [SNP] at TNF-I+ promoter region with TNF receptor 2 (TNFR2) in susceptibility to pulmonary tuberculosis; using PCR-RFLP technique. ( 28078191 )
2016
32
Organizing pneumonia and pulmonary tuberculosis: Coexistent or associated diseases. ( 27156206 )
2016
33
Association of TAP1 and TAP2 Gene Polymorphisms with Susceptibility to Pulmonary Tuberculosis. ( 26996113 )
2016
34
Hematological and Biochemistry Profile and Risk Factors Associated with Pulmonary Tuberculosis Patients in Guyana. ( 27190646 )
2016
35
Pulmonary tuberculosis: Resistance pattern to first line anti-tuberculosis drugs in the Coimbra District, 2000-2011. ( 27216567 )
2016
36
Predictors of Treatment Outcome for Retreatment Pulmonary Tuberculosis Cases among Tribal People of an Eastern India District: A Prospective Cohort Study. ( 27656293 )
2016
37
Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients with Acute Respiratory Failure: A Propensity Analysis of Mortality. ( 27609755 )
2016
38
The value of initial cavitation to predict re-treatment with pulmonary tuberculosis. ( 27154410 )
2016
39
Identification potential biomarkers in pulmonary tuberculosis and latent infection based on bioinformatics analysis. ( 27655333 )
2016
40
Carcinomatous pleuritis and pericarditis accompanied by pulmonary tuberculosis. ( 28031837 )
2016
41
Association of genetic polymorphisms of CISH with the risk of pulmonary tuberculosis in Zahedan, Southeast Iran. ( 27266592 )
2016
42
[Increased serum levels of soluble T cell immunoglobulin mucin molecule 3 and IL-4 and decreased IFN-I^ in patients with pulmonary tuberculosis]. ( 27363280 )
2016
43
Proposed Approach for 4-Month Treatment of Culture-Negative Pulmonary Tuberculosis in Adults. ( 27627478 )
2016
44
Vitamin D receptor gene associations with pulmonary tuberculosis in a Tibetan Chinese population. ( 27595605 )
2016
45
Tip of nose tuberculosis: A rare presentation of extra pulmonary tuberculosis. ( 27195200 )
2016
46
IRGM gene polymorphisms and haplotypes associate with susceptibility of pulmonary tuberculosis in Chinese Hubei Han population. ( 26786655 )
2016
47
Effective testing for pulmonary tuberculosis using Xpert MTB/RIF assay for stool specimens in immunocompetent Pakistani children. ( 28043630 )
2016
48
Mortality among pulmonary tuberculosis and HIV-1 co-infected Nigerian children being treated for pulmonary tuberculosis and on antiretroviral therapy: a retrospective cohort study. ( 28053917 )
2016
49
A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. ( 27155189 )
2016
50
Evaluation of a whole-blood chemiluminescent immunoassay of IFN-I^, IP-10, and MCP-1 for diagnosis of active pulmonary tuberculosis and tuberculous pleurisy patients. ( 27523388 )
2016

Variations for Pulmonary Tuberculosis

Expression for Pulmonary Tuberculosis

LifeMap Discovery
Genes differentially expressed in tissues of Pulmonary Tuberculosis patients vs. healthy controls: 35 (show all 44)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GBP6 guanylate binding protein family, member 6 Blood + 4.38 0.000
2 ANKRD22 ankyrin repeat domain 22 Blood + 4.04 0.000
3 PDCD1LG2 programmed cell death 1 ligand 2 Blood + 4.03 0.000
4 RLTPR RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing Blood - 3.89 0.000
5 CD274 CD274 molecule Blood + 3.87 0.000
6 CD248 CD248 molecule, endosialin Blood - 3.84 0.000
7 SPIB Spi-B transcription factor (Spi-1/PU.1 related) Blood - 3.81 0.000
8 LRRN3 leucine rich repeat neuronal 3 Blood - 3.61 0.000
9 LINC00668 long intergenic non-protein coding RNA 668 Blood + 3.60 0.000
10 C1QC complement component 1, q subcomponent, C chain Blood + 3.56 0.000
11 CR1 complement component (3b/4b) receptor 1 (Knops blood group) Blood + 3.54 0.000
12 AEBP1 AE binding protein 1 Blood - 3.53 0.000
13 KREMEN1 kringle containing transmembrane protein 1 Blood + 3.49 0.000
14 CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit Blood + 3.46 0.000
15 LGALSL lectin, galactoside-binding-like Blood - 3.43 0.000
16 BATF2 basic leucine zipper transcription factor, ATF-like 2 Blood + 3.42 0.000
17 PLEKHB1 pleckstrin homology domain containing, family B (evectins) member 1 Blood - 3.40 0.000
18 CD22 CD22 molecule Blood - 3.38 0.000
19 BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 Blood + 3.38 0.000
20 NAIP NLR family, apoptosis inhibitory protein Blood + 3.34 0.000
21 EPHB6 EPH receptor B6 Blood - 3.30 0.000
22 DICER1 dicer 1, ribonuclease type III Blood + 3.26 0.000
23 MVD mevalonate (diphospho) decarboxylase Blood - 3.26 0.000
24 FBLN2 fibulin 2 Blood - 3.26 0.000
25 FBXL16 F-box and leucine-rich repeat protein 16 Blood - 3.23 0.000
26 CR2 complement component (3d/Epstein Barr virus) receptor 2 Blood - 3.21 0.000
27 PRSS33 protease, serine, 33 Blood - 3.21 0.000
28 FGF13 fibroblast growth factor 13 Blood + 3.20 0.000
29 GNPNAT1 glucosamine-phosphate N-acetyltransferase 1 Blood - 3.19 0.000
30 RTKN2 rhotekin 2 Blood - 3.19 0.000
31 EPHA1 EPH receptor A1 Blood - 3.16 0.000
32 APOL6 apolipoprotein L, 6 Blood + 3.16 0.000
33 CRIP2 cysteine-rich protein 2 Blood - 3.15 0.000
34 C1QB complement component 1, q subcomponent, B chain Blood + 3.15 0.000
35 CARD17 caspase recruitment domain family, member 17 Blood + 3.14 0.000
36 SERINC5 serine incorporator 5 Blood - 3.12 0.000
37 HKDC1 hexokinase domain containing 1 Blood - 3.11 0.000
38 NT5E 5'-nucleotidase, ecto (CD73) Blood - 3.10 0.000
39 LINC00342 long intergenic non-protein coding RNA 342 Blood + 3.10 0.000
40 PMEPA1 prostate transmembrane protein, androgen induced 1 Blood - 3.09 0.000
41 FCGBP Fc fragment of IgG binding protein Blood - 3.07 0.000
42 SALL2 spalt-like transcription factor 2 Blood - 3.06 0.000
43 GPA33 glycoprotein A33 (transmembrane) Blood - 3.02 0.000
44 SLC27A5 solute carrier family 27 (fatty acid transporter), member 5 Blood - 3.00 0.000
Search GEO for disease gene expression data for Pulmonary Tuberculosis.

Pathways for Pulmonary Tuberculosis

Pathways related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CCL3 HLA-DRB1 HP IFNG IFNGR1 IL10
2
Show member pathways
13.7 CCL3 IFNG IFNGR1 IL10 IL12RB1 IL18
3
Show member pathways
13.58 CCL3 IFNG IFNGR1 IL10 IL12RB1 IL18
4
Show member pathways
13.45 CCL3 IL10 IL12RB1 IL18 IL2 IL4
5
Show member pathways
13.43 CCL3 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1
6
Show member pathways
13.34 CCL3 IL10 IL12RB1 IL18 IL2 IL4
7
Show member pathways
13.24 HLA-DRB1 IFNG IFNGR1 IL2 IL4 TLR2
8
Show member pathways
12.98 CCL3 IFNG IFNGR1 IL10 IL2 MBL2
9
Show member pathways
12.9 HLA-DRB1 IFNG IL10 IL2 IL4 TNF
10
Show member pathways
12.85 HLA-DRB1 IFNG IFNGR1 IL18 IL2 IL4
11
Show member pathways
12.66 IFNG IL10 IL12RB1 IL18 IL2 TNF
12 12.61 IFNG IL10 IL2 IL4 TLR2 TNF
13
Show member pathways
12.61 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
14
Show member pathways
12.57 IFNG IFNGR1 IL2 IL4 TNF
15
Show member pathways
12.49 IFNG IL10 IL2 IL4 TNF
16
Show member pathways
12.39 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
17
Show member pathways
12.36 IFNG IL2 IL4 TNF
18
Show member pathways
12.36 IFNG IL4 TLR2 TNF
19
Show member pathways
12.28 IFNG IFNGR1 IL10 IL12RB1 IL2 IL4
20
Show member pathways
12.27 HLA-DRB1 IFNG IFNGR1 IL10 IL4 TLR2
21
Show member pathways
12.26 IFNG IFNGR1 IL4 TLR2 TNF
22 12.22 IFNG IFNGR1 TLR2 TNF
23
Show member pathways
12.21 IFNG IL10 IL18 IL2 IL4 TNF
24 12.18 HLA-DRB1 IFNG IFNGR1 IL10 IL18 TLR2
25 12.09 IFNG IL10 IL2 IL4 TNF
26 12.06 IFNG IL2 IL4 TNF
27 12.04 IL10 IL18 IL4 TNF
28
Show member pathways
11.98 IFNG IL12RB1 IL4 TLR2
29
Show member pathways
11.97 CCL3 HLA-DRB1 IFNG IL12RB1 IL18 IL2
30 11.95 IFNG IL10 TLR2 TNF
31 11.9 CCL3 IFNG IFNGR1 IL18
32 11.86 CCL3 HLA-DRB1 IFNG IL18 TLR2 TNF
33
Show member pathways
11.84 IFNG IL2 IL4 TNF
34 11.84 IFNG IL10 IL2 TNF
35 11.82 IFNG IL2 IL4
36 11.8 IL10 IL4 TLR2 TNF
37 11.77 IFNG IFNGR1 IL10 IL12RB1 IL2
38 11.7 CCL3 IL4 TNF
39
Show member pathways
11.7 IFNG IL2 TNF
40
Show member pathways
11.68 IFNG IL2 TNF
41 11.64 HLA-DRB1 IL10 MBL2
42 11.63 IL18 TLR2 TNF
43 11.62 IFNG IL18 TLR2 TNF
44 11.6 IFNG IL10 IL2 IL4
45 11.6 CCL3 IL10 IL18 IL4 TNF
46 11.59 IFNG IL2 TNF
47
Show member pathways
11.59 IFNG IFNGR1 IL10 IL12RB1 IL18 IL2
48
Show member pathways
11.58 IFNG IFNGR1 TNF
49 11.58 IFNG IL10 IL18 TLR2 TNF
50 11.56 IFNG IL2 TNF

GO Terms for Pulmonary Tuberculosis

Cellular components related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 CCL3 HP IFNG IL10 IL18 IL2
2 extracellular space GO:0005615 9.7 ADA CCL3 HP IFNG IL10 IL18
3 external side of plasma membrane GO:0009897 9.17 ADA HLA-DRB1 IFNG IL12RB1 IL4 P2RX7

Biological processes related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.98 IL10 P2RX7 SLC11A1 TLR2
2 positive regulation of protein phosphorylation GO:0001934 9.96 IFNG IL2 IL4 P2RX7 TNF
3 defense response to bacterium GO:0042742 9.93 HP IFNG IL10 MBL2 SLC11A1 TNF
4 positive regulation of gene expression GO:0010628 9.91 CCL3 IFNG P2RX7 SLC11A1 TLR2 TNF
5 cellular response to organic cyclic compound GO:0071407 9.88 CCL3 IL18 P2RX7 TNF
6 defense response to Gram-positive bacterium GO:0050830 9.88 MBL2 P2RX7 TLR2 TNF
7 positive regulation of protein kinase B signaling GO:0051897 9.87 CCL3 IL18 TNF
8 negative regulation of inflammatory response GO:0050728 9.87 ADA IL10 IL2
9 positive regulation of inflammatory response GO:0050729 9.87 CCL3 IL18 IL2 TLR2
10 interferon-gamma-mediated signaling pathway GO:0060333 9.86 HLA-DRB1 IFNG IFNGR1
11 positive regulation of T cell proliferation GO:0042102 9.86 IFNG IL2 IL4
12 positive regulation of tumor necrosis factor production GO:0032760 9.85 CCL3 IFNG TLR2
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IFNG IL18 IL2 IL4
14 positive regulation of interleukin-6 production GO:0032755 9.84 P2RX7 TLR2 TNF
15 extrinsic apoptotic signaling pathway GO:0097191 9.83 IFNG P2RX7 TNF
16 positive regulation of B cell proliferation GO:0030890 9.81 ADA IL2 IL4
17 positive regulation of phagocytosis GO:0050766 9.8 MBL2 SLC11A1 TNF
18 positive regulation of cytokine secretion GO:0050715 9.79 IL10 P2RX7 TNF
19 positive regulation of interleukin-1 beta secretion GO:0050718 9.78 CCL3 IFNG P2RX7
20 positive regulation of NF-kappaB import into nucleus GO:0042346 9.77 IL18 TLR2 TNF
21 positive regulation of T cell differentiation GO:0045582 9.77 ADA IL2 IL4
22 negative regulation of nitric oxide biosynthetic process GO:0045019 9.71 IL10 IL4
23 response to molecule of bacterial origin GO:0002237 9.71 IL10 TLR2
24 positive regulation of interleukin-17 production GO:0032740 9.71 IL18 IL2
25 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.71 IFNG IFNGR1
26 positive regulation of chemokine biosynthetic process GO:0045080 9.71 IFNG IL4 TNF
27 lipopolysaccharide-mediated signaling pathway GO:0031663 9.71 CCL3 IL18 TLR2 TNF
28 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL10 TNF
29 positive regulation of T cell mediated cytotoxicity GO:0001916 9.7 IL12RB1 P2RX7
30 positive regulation of isotype switching to IgG isotypes GO:0048304 9.7 IFNG IL2 IL4
31 T-helper 1 type immune response GO:0042088 9.69 HLA-DRB1 IL18
32 positive regulation of T-helper 1 type immune response GO:0002827 9.69 IL12RB1 SLC11A1
33 endothelial cell apoptotic process GO:0072577 9.68 IL10 TNF
34 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 IL10 TNF
35 positive regulation of tissue remodeling GO:0034105 9.67 IL18 IL2
36 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IFNG IL10 IL4
37 regulation of isotype switching GO:0045191 9.65 IL10 IL4
38 negative regulation of T-helper 17 cell differentiation GO:2000320 9.65 IL2 IL4
39 positive regulation of mononuclear cell migration GO:0071677 9.65 IL4 TNF
40 receptor biosynthetic process GO:0032800 9.63 IL10 TNF
41 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.63 IFNG TNF
42 positive regulation of activated T cell proliferation GO:0042104 9.62 IL12RB1 IL18 IL2 IL4
43 positive regulation of vitamin D biosynthetic process GO:0060557 9.61 IFNG TNF
44 type 2 immune response GO:0042092 9.61 IL10 IL18 IL4
45 defense response to protozoan GO:0042832 9.56 IFNG IL10 IL4 SLC11A1
46 negative regulation of growth of symbiont in host GO:0044130 9.46 IFNG IL10 MBL2 TNF
47 positive regulation of interferon-gamma production GO:0032729 9.35 IL12RB1 IL18 IL2 SLC11A1 TNF
48 immune response GO:0006955 9.32 CCL3 HLA-DRB1 IFNG IL10 IL18 IL2
49 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.16 IFNG IL10 IL18 IL2 IL4 SLC11A1
50 response to drug GO:0042493 10.06 ADA IFNG IL10 IL4 P2RX7

Molecular functions related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 INHA
2 cytokine activity GO:0005125 9.23 CCL3 IFNG IL10 IL18 IL2 IL4

Sources for Pulmonary Tuberculosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....